Logo: to the web site of Uppsala University

uu.sePublikasjoner fra Uppsala universitet
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective
Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA.
Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
Janssen Res & Dev, Discovery Sci, Computat Chem, Beerse, Belgium.
Temple Univ, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 104, nr 5, s. 818-835Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Membrane transporters play diverse roles in the pharmacokinetics and pharmacodynamics of small-molecule drugs. Understanding the mechanisms of drug-transporter interactions at the molecular level is, therefore, essential for the design of drugs with optimal therapeutic effects. This white paper examines recent progress, applications, and challenges of molecular modeling of membrane transporters, including modeling techniques that are centered on the structures of transporter ligands, and those focusing on the structures of the transporters. The goals of this article are to illustrate current best practices and future opportunities in using molecular modeling techniques to understand and predict transporter-mediated effects on drug disposition and efficacy. Membrane transporters from the solute carrier (SLC) and ATP-binding cassette (ABC) superfamilies regulate the cellular uptake, efflux, and homeostasis of many essential nutrients and significantly impact the pharmacokinetics of drugs(1-4); further, they may provide targets for novel therapeutics as well as facilitate prodrug approaches.(5,6) Because of their often broad substrate selectivity they are also implicated in many undesirable and sometimes life-threatening drug-drug interactions (DDIs).(5,6)

sted, utgiver, år, opplag, sider
John Wiley & Sons, 2018. Vol. 104, nr 5, s. 818-835
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-369940DOI: 10.1002/cpt.1174ISI: 000448068500012PubMedID: 29981151OAI: oai:DiVA.org:uu-369940DiVA, id: diva2:1272248
Forskningsfinansiär
NIH (National Institute of Health), R01 GM108911, R01 DK061425Åke Wiberg FoundationTilgjengelig fra: 2018-12-18 Laget: 2018-12-18 Sist oppdatert: 2022-10-31bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Person

Matsson, Pär

Søk i DiVA

Av forfatter/redaktør
Matsson, Pär
Av organisasjonen
I samme tidsskrift
Clinical Pharmacology and Therapeutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 72 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf